Question 1

What is the catalog number for EO-1606?

Accepted Answer

The catalog number for EO-1606 is M34588.

Question 2

What sizes are available for EO-1606?

Accepted Answer

EO-1606 is available in the following size(s): 1 g, 500 mg, 200 mg, 5 mg, 10 mg, 25 mg, 50 mg.

Question 3

How many pack sizes does EO-1606 come in?

Accepted Answer

EO-1606 is available in 7 different pack sizes.

Question 4

Is EO-1606 in stock?

Accepted Answer

EO-1606 is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What is EO-1606 used for?

Accepted Answer

EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer; s disease and dermatitis.

Question 6

How do I reconstitute this lyophilized product?

Accepted Answer

Reconstitution instructions, including the recommended diluent and final concentration, are provided on the datasheet. Aliquot immediately after reconstitution to avoid repeated freeze-thaw cycles.

Question 7

What is the recommended incubation time for this antibody?

Accepted Answer

A suggested incubation time is provided in the recommended protocol on the datasheet, but may need adjusting depending on your sample type and detection system.

Question 8

What should I check when this product first arrives?

Accepted Answer

Inspect the package immediately for transportation damage, ice loss, leakage, or breakage. Report any issues right away with photos and your order reference; our specialists will determine whether the product is still usable or needs replacing.

EO-1606

Product Specifications

CAS Number

Stability

Purity

Weight

Molecular Formula

Notes

Receptor

Available Sizes

Frequently Asked Questions

Explore Other Products

Ground clamp made of

Human Retinol-binding protein-2 (RBP-2) ELISA Kit

Human Retinol-binding protein-2 (RBP-2) ELISA Kit

FYCO1 Peptide - N-terminal region

Lentiviral human CATSPER3 shRNA (UAS) - Lentiviral human CATSPER3 shRNA (UAS) (25)

Vimentin, phosphorylated (Tyr38) discontinued